NL-OMON27469招募中不适用
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal cancer
eiden University Medical Center (LUMC)0 个研究点目标入组 34 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 34
研究概览
简要总结
.A.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Part A (healthy volunteers)
- •A maximum of sixteen (16) healthy volunteers will take part in this study.
排除标准
- •Part A (healthy volunteers)
- •A maximum of sixteen (16) healthy volunteers will take part in this study.
研究者
相似试验
已完成
不适用
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal canceresophageal/gastric- or colorectal cancer10017990NL-OMON48830eids Universitair Medisch Centrum34
进行中（未招募）
1 期
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-005761-23-SECyclo Therapeutics, Inc.11
进行中（未招募）
1 期
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0 Level: PT Classification code 10029403 Term: Niemann-Pick disease System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-005761-23-GBCTD Holdings, Inc.12
进行中（未招募）
1 期
A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Niemann-Pick disease type C (NPC-1) to assess what the drug does to the body, and what the body does to the drug, and the side effects and benefits experienced by patientsiemann-Pick disease type CMedDRA version: 20.0Level: PTClassification code 10029403Term: Niemann-Pick diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-005761-23-ITCTD HOLDINGS, INC.12
进行中（未招募）
1 期
A study evaluating the safety and activity of a new drug - pegylated recombinant hyman arginase (BCT-100) in cancers in children and young people that have come back (relapsed) or have not responded to treatment (refractory).Relpased/refractory paeditaric cancers:LeukaemiasSarcomaNeuroblastomaHigh grade glioma (brain cancers)MedDRA version: 21.0Level: PTClassification code 10000830Term: Acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10039494Term: Sarcoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002762-44-IEniversity of Birmingham64